Literature DB >> 20599198

Circulating lymphotoxin β receptor and atherosclerosis: observations from the Dallas Heart Study.

Andrew W Owens1, Susan Matulevicius, Anand Rohatgi, Colby R Ayers, Sandeep R Das, Amit Khera, Darren K McGuire, James A de Lemos.   

Abstract

OBJECTIVE: Lymphotoxin β receptor (LTβR), a member of the tumor necrosis factor superfamily, binds ligands expressed by activated lymphocytes. Interruption of LTβR signaling improves autoimmune diseases and alters lipid homeostasis. We assayed circulating LTβR and examined its association with atherosclerosis phenotypes in a population-based sample. METHODS AND
RESULTS: Plasma LTβR was measured by ELISA in 3215 subjects enrolled in the Dallas Heart Study. Atherosclerosis was assessed using CT measurements of coronary calcium (CAC) and abdominal MRI measurements of aortic plaque (AP) (n=2252) and aortic wall thickness (AWT) (n=2265). We analyzed associations between LTβR and atherosclerosis using multivariable logistic and linear regression methods. Higher levels of LTβR associated with most traditional cardiovascular risk factors, multiple inflammatory markers, and markers of cardiac injury. Univariable analyses demonstrated significant associations of LTβR with CAC, AP, and AWT (p<0.0001 for each). In multivariable models adjusted for traditional risk factors, the 4th vs. the 1st quartile of LTβR remained associated with prevalent CAC, AP, and increased AWT (all p<0.05). Similar associations were observed when LTβR was modeled as a log-transformed continuous variable.
CONCLUSION: LTβR levels are independently associated with atherosclerosis in multiple vascular beds. These findings support further investigation of the lymphotoxin/LTβR pathway in atherosclerosis.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599198     DOI: 10.1016/j.atherosclerosis.2010.06.003

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

Review 1.  T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword.

Authors:  Karin H Simons; Alwin de Jong; J Wouter Jukema; Margreet R de Vries; Ramon Arens; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2019-06       Impact factor: 32.419

Review 2.  TWEAK: A New Player in Obesity and Diabetes.

Authors:  Joan Vendrell; Matilde R Chacón
Journal:  Front Immunol       Date:  2013-12-30       Impact factor: 7.561

3.  Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study.

Authors:  Andrew Lin; Nathan D Wong; Aryabod Razipour; Priscilla A McElhinney; Frederic Commandeur; Sebastien J Cadet; Heidi Gransar; Xi Chen; Stephanie Cantu; Robert J H Miller; Nitesh Nerlekar; Dennis T L Wong; Piotr J Slomka; Alan Rozanski; Balaji K Tamarappoo; Daniel S Berman; Damini Dey
Journal:  Cardiovasc Diabetol       Date:  2021-01-29       Impact factor: 9.951

4.  The association of lymphotoxin-beta receptor with the subsequent diagnosis of incident gastrointestinal cancer: results from the Dallas Heart Study.

Authors:  Colin P Bergstrom; Muhammad S Beg; Colby Ayers; Arjun Gupta; Ian J Neeland
Journal:  J Gastrointest Oncol       Date:  2020-02

5.  Genetic-genomic replication to identify candidate mouse atherosclerosis modifier genes.

Authors:  Jeffrey Hsu; Jonathan D Smith
Journal:  J Am Heart Assoc       Date:  2013-01-23       Impact factor: 5.501

6.  A combined clinical and biomarker approach to predict diuretic response in acute heart failure.

Authors:  Jozine M ter Maaten; Mattia A E Valente; Marco Metra; Noemi Bruno; Christopher M O'Connor; Piotr Ponikowski; John R Teerlink; Gad Cotter; Beth Davison; John G Cleland; Michael M Givertz; Daniel M Bloomfield; Howard C Dittrich; Dirk J van Veldhuisen; Hans L Hillege; Kevin Damman; Adriaan A Voors
Journal:  Clin Res Cardiol       Date:  2015-08-18       Impact factor: 5.460

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.